1 / 3

General Session 4: Pharmacogenomics

General Session 4: Pharmacogenomics. FDA Pharmacogenomic Guidances. April 2003, CDRH: Multiplex Tests for Heritable DNA Markers, Mutations and Expression Patterns: Draft Guidance for Industry and FDA Reviewers. http://www.fda.gov/cdrh/oivd/guidance/1210.pdf

dominique
Télécharger la présentation

General Session 4: Pharmacogenomics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. General Session 4: Pharmacogenomics

  2. FDA Pharmacogenomic Guidances April 2003, CDRH: Multiplex Tests for Heritable DNA Markers, Mutations and Expression Patterns:Draft Guidance for Industry and FDA Reviewers. http://www.fda.gov/cdrh/oivd/guidance/1210.pdf March 2004, CDER:Pharmacogenomic Data Submissions. http://www.fda.gov/cber/gdlns/pharmdtasub.htm April 2005, CDER/CDRH/CBER/OCP: Drug-Diagnostic Co-development Concept Paper http://www.fda.gov/cder/genomics/pharmacoconceptfn.pdf

  3. Roche AmpliChip CYP450 Test (CDRH de novo 510(k) K042259) Genotypes two cytochrome P450 genes (29 polymorphisms in CYP2D6 gene, 2 in CYP2C19) to provide the predictive phenotype of the metabolic rate for a class of therapeutics metabolized primarily by CYP2D6 or CYP2C19 gene products. The phenotypes are (1) Poor metabolizers: (3) Extensive metabolizers: (2) Intermediate metabolizers: (4) Ultrarapid metabolizers: Cytochrome P450s are a large multi-gene family of enzymes found in the liver, and are linked to the metabolism of approximately 70-80% of all drugs. Among them, the polymorphic CYP2D6 and CYP2C19 genes are responsible for approximately 25% of all CYP450-mediated drug metabolism. A polymorphism in these enzymes can lead to an excessive or prolonged therapeutic effect or drug-related toxicity after a typical dose by failing to clear a drug from the blood or by changing the pattern of metabolism to produce toxic metabolites. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm

More Related